Patients to benefit from updated skin tumour publications
26 October 2018
Healthcare professionals specialising in skin cancers, including melanoma, now have access to two publications with the most current information relating to skin tumour diagnosis and management. Both publications – the WHO Classification of Skin Tumours, 4th Edition, and Pathology of Melanocytic Tumours – are co-edited by Professor Richard Scolyer, Co-Medical Director of Melanoma Institute Australia (MIA), and will have a major impact on the diagnosis and management of melanoma and other skin tumours.
The WHO Classification of Skin Tumours, 4th Edition integrates diagnostic information and pathological features of skin tumours with the latest in molecular, genetic and epidemiological information. This edition of the WHO Skin Blue Book has substantially updated the classification of melanoma and is a breakthrough publication that every pathologist, dermatopathologist, dermatologist, oncologist and other health care professionals who deal with skin tumours should have.
A separate textbook Professor Scolyer has edited with other world authorities from the USA is Pathology of Melanocytic Tumours. Constituting a large percentage of everyday diagnostic practice, melanocytic pathology is a complex and challenging area with many difficult-to-diagnose lesions. This highly illustrated reference, written by three of the world’s leading dermatopathologists, provides authoritative guidance in the accurate diagnosis of even the most challenging pigmented skin tumours.
‘These publications will undoubtedly assist the care of patients with melanoma and other skin cancers world-wide,” Professor Scolyer said.
Australasian Melanoma Conference AMC2021
The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.
Sharing our knowledge of melanoma on the global stage
As leaders in the field of melanoma, clinicians and researchers from MIA will be sharing their knowledge at the virtual 10th World Congress of Melanoma.
Community Fundraising Wrap Up Jan-Mar 2021
The easing of COVID restrictions has meant the return of community events, and we recognise the generous support of our community fundraisers.
Melanoma patients and their families urged to speak up and put national spotlight on melanoma.
Melanoma patients and their carers are being urged to participate in a ground-breaking survey which will shape the future of melanoma treatment, research, support and funding in Australia.
Support for Melanoma March has come from everywhere
We have been buoyed by the wonderful support for our Melanoma March campaign, and our mission to cover Australia in footprints continues into April!
An inspiring WA Melanoma Community Forum
There was a wonderful feeling of community support amongst the melanoma patients, families and friends at the WA Melanoma Community Form.
Family of 8-year-old with melanoma calls on all Australians to step up to help save lives
The Price family has decided to share their story to inspire Australians to support research into new melanoma treatments.
Rethinking skin surveillance for high-risk melanoma patients
New research has provided evidence in favour of a structured skin surveillance program for high-risk melanoma patients.
Australia's oldest melanoma survivor steps up to save lives on his 105th birthday
Melanoma research saved Bert's life at 101 and now he wants to give back.
Predicting disease spread in thin melanoma
A new MIA online risk calculator for clinicians can determine the likelihood of thin melanoma spreading.
Exploring our own clinical questions through MIA's new trials initiative
MIA has recently established a new division of our Clinical Trials Program which co-ordinates and manages investigator-led multi-centre trials.
Young researchers awarded Fellowships to pursue innovative treatments for melanoma
Two young researchers from MIA and The University of Sydney awarded Cancer Institute NSW fellowships.
Young researchers receive boost to develop innovative treatment for melanoma
Two young researchers from MIA and The University of Sydney awarded Cancer Institute NSW fellowships.
Launch of Melanoma March 2021
Aussies urged to leave their footprint on melanoma as efforts step up to save lives from the disease.
Olivia Vivian announced as MIA ambassador
Olivia is using her Ninja star power to shine a spotlight on melanoma prevention - in memory of her dad.
Melanoma breakthrough - neoadjuvant treatment saving lives.
Drug treatment before surgery, known as neoadjuvant therapy, is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy.
Melanoma breakthrough - neoadjuvant therapy saving lives.
Drug treatment before surgery, known as neoadjuvant therapy, is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy.
Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?
New research, led by MIA, has revealed that cancer patients treated with immunotherapy are not at a higher risk of developing severe COVID-19 infection compared to other cancer patients.
Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?
New research, led by MIA, has revealed that cancer patients treated with immunotherapy are not at a higher risk of developing severe COVID-19 infection compared to other cancer patients.
A message to all Australians from melanoma patient Stuart Taylor
Stuart has advanced melanoma which is not responding to treatment. He has shared his story on ABC's 7:30 in the hope that others can escape the same fate.